<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Metabolic bone disease in inflammatory bowel disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Metabolic bone disease in inflammatory bowel disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Metabolic bone disease in inflammatory bowel disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Harold N Rosen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Deborah E Sellmeyer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sunanda V Kane, MD, MSPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteoporosis is common in patients with inflammatory bowel diseases (IBD) such as Crohn disease (CD) or ulcerative colitis (UC). In cross-sectional studies of patients with IBD, the prevalence of osteoporosis ranges from 18 to 42 percent [
         <a href="#rid1">
          1,2
         </a>
         ]. In patients newly diagnosed with IBD, the prevalence is much lower (0 to 5 percent) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The etiology of low bone mass is multifactorial and includes corticosteroid therapy, disease-related inflammatory activity, dietary restrictions, malabsorption, and hypogonadism [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         This topic review will focus on the risk factors for and the evaluation and treatment of bone disease in patients with IBD. The diagnosis and treatment of osteoporosis in pre- and postmenopausal women and men and the prevention and treatment of glucocorticoid-induced osteoporosis are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          SKELETAL OUTCOMES
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Bone mineral density
         </span>
         <span class="headingEndMark">
          —
         </span>
         In cross-sectional studies, osteoporosis (T-score &lt;-2.5) has been noted in approximately 18 to 42 percent of patients with established IBD [
         <a href="#rid1">
          1,2
         </a>
         ]. The prevalence of osteopenia (T-score between -1 and -2.5) ranges from 22 to 77 percent [
         <a href="#rid4">
          4
         </a>
         ]. In a meta-analysis of 16 studies of bone mineral density (BMD) in IBD compared with controls, the mean Z-scores at all sites were lower in patients with IBD (mean difference ranging from -0.5 to -1) [
         <a href="#rid5">
          5
         </a>
         ]. In some [
         <a href="#rid6">
          6-9
         </a>
         ], but not all [
         <a href="#rid10">
          10-15
         </a>
         ], studies, low bone mass is more common in patients with Crohn disease (CD) than ulcerative colitis (UC).
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Fracture
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some [
         <a href="#rid16">
          16-18
         </a>
         ], but not all [
         <a href="#rid19">
          19
         </a>
         ], population-based studies, there was an increased risk of fracture in individuals with IBD. In the largest study (6027 patients with IBD), the overall fracture rate was higher than that for controls (relative risk [RR] 1.4, 95% CI 1.3-1.6) [
         <a href="#rid16">
          16
         </a>
         ]. The increased risk occurred primarily in older (&gt;60 years) patients. There was no difference between UC and CD. In a meta-analysis of studies that evaluated specific types of fractures in patients with IBD, there was an increase in risk of vertebral fracture (1.34 versus 0.56 percent in healthy controls, odds ratio [OR] 2.26, 95% CI 1.04-4.90) [
         <a href="#rid5">
          5
         </a>
         ]. The increase in risk of hip fracture was not significant (2.4 versus 1.7 percent, OR 1.29, 95% CI 0.84-1.96). In one of the studies, risk of fracture increased with duration of corticosteroid use [
         <a href="#rid20">
          20
         </a>
         ]. Although low BMD is a risk for fracture, many individuals have normal BMD at the time of fracture diagnosis [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with IBD are at risk for osteoporosis and fracture for several reasons, including disease-related inflammatory activity, corticosteroid therapy, hypogonadism, and nutritional deficiencies [
         <a href="#rid4">
          4,22
         </a>
         ]. Advanced age and low body mass index (BMI) further increase risk [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Disease-related inflammatory activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with IBD have low bone mineral density (BMD) in the absence of other identifiable risk factors. This can be illustrated by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some patients with Crohn disease (CD) have a low BMD at the time of diagnosis, before any treatment is given [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osteoporosis is common in patients with IBD who have received little corticosteroid and who are vitamin D replete [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The cause of low BMD in these untreated patients is not understood. In some cases, bone resorption is increased without a compensatory increase in bone formation. One possibility is that the chronic inflammatory state leads to increased intestinal production of cytokines (eg, interleukins 1 and 6, tumor necrosis factor [TNF]) that stimulate bone resorption [
         <a href="#rid1">
          1,4,22,25
         </a>
         ]. In support of this hypothesis is the finding that maintenance treatment with the anti-TNF,
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         , was associated with improvement in BMD in patients with CD, implicating a role for TNF-alpha in bone loss. (See
         <a class="medical medical_review" href="/z/d/html/4077.html" rel="external">
          "Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">
          "Medical management of moderate to severe Crohn disease in adults"
         </a>
         .)
        </p>
        <p>
         Changes in the RANKL (receptor activator of NF-kappa B ligand)/OPG (osteoprotegerin) system may also contribute to low bone mass in patients with IBD [
         <a href="#rid26">
          26,27
         </a>
         ]. RANKL is expressed by cells of the osteoblast lineage. It interacts with a receptor on osteoclast precursors called RANK. The RANKL/RANK interaction results in activation of cells in the osteoclast lineage to begin the process of osteoclastogenesis and bone resorption. However, RANKL can also bind to a soluble decoy receptor called OPG. OPG blocks the interaction of RANKL and RANK, thereby preventing osteoclast activation and bone resorption. (See
         <a class="medical medical_review" href="/z/d/html/2053.html" rel="external">
          "Normal skeletal development and regulation of bone formation and resorption", section on 'Osteoclasts'
         </a>
         .)
        </p>
        <p>
         In one study of patients with IBD, plasma OPG and RANKL were elevated and correlated with BMD [
         <a href="#rid27">
          27
         </a>
         ]. Further studies are required to assess the role of the RANKL/RANK/OPG system in bone loss in patients with IBD. If RANKL is shown to play an important role,
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         , a monoclonal antibody to RANKL, may prove to be an effective therapy for osteoporosis in IBD. (See
         <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">
          "Denosumab for osteoporosis", section on 'Mechanism of action'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Glucocorticoid therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with IBD receive glucocorticoids to reduce intestinal inflammation. Glucocorticoids cause bone loss by inhibiting bone formation, increasing bone resorption, decreasing intestinal absorption of calcium, and increasing renal excretion of calcium. (See
         <a class="medical medical_review" href="/z/d/html/2032.html" rel="external">
          "Clinical features and evaluation of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p>
         Bone loss is more common in patients with IBD who have been treated with glucocorticoids [
         <a href="#rid8">
          8
         </a>
         ]. In one report, for example, the incidence of osteopenia was approximately twice as high (52 versus 28 percent) in patients who had been treated with corticosteroids compared with those who had not [
         <a href="#rid11">
          11
         </a>
         ]. In general, BMD in patients with IBD is inversely correlated with lifetime corticosteroids dose [
         <a href="#rid3">
          3,6,10,11,13,28
         </a>
         ]. However, it is difficult to distinguish the adverse skeletal effects of corticosteroids from those of disease-related inflammatory activity because the two factors are often linked [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Alterations in sex hormone status
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypogonadism is common in both males and females with IBD, probably because of the inhibitory effects of the illness and corticosteroid therapy on pituitary-gonadal function [
         <a href="#rid29">
          29
         </a>
         ]. In males, corticosteroid therapy lowers serum testosterone concentrations by approximately one-third, primarily by inhibiting gonadotropin secretion [
         <a href="#rid30">
          30
         </a>
         ]. Gonadal steroid deficiency is a well-recognized cause of osteoporosis in both males and females. (See
         <a class="medical medical_review" href="/z/d/html/2049.html" rel="external">
          "Etiology of osteoporosis in men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2058.html" rel="external">
          "Epidemiology and etiology of premenopausal osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Vitamin D and calcium insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vitamin D insufficiency is common in patients with IBD. In one study, 65 percent of patients with CD had low serum calcidiol (25-hydroxyvitamin D) concentrations [
         <a href="#rid31">
          31
         </a>
         ]. This problem is in part due to malabsorption, particularly in patients with CD who have a history of small bowel resection  (
         <a class="graphic graphic_figure graphicRef70661" href="/z/d/graphic/70661.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid32">
          32
         </a>
         ]. Avoidance of dairy products may also contribute to vitamin D insufficiency. One study, for example, found that dietary calcium intake below 1000 mg/day was more common in patients with CD than in individuals without IBD (53 versus 27 percent) [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         However, BMD is reduced even in many patients who are vitamin D replete [
         <a href="#rid11">
          11,12
         </a>
         ]. Thus, vitamin D deficiency is not the main cause of osteoporosis in most patients with IBD.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Other nutritional deficiencies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Macronutrient (protein, overall calories) and micronutrient (vitamins and minerals) deficiencies are common in patients with IBD, including patients maintained on
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ], and may contribute to bone disease. (See
         <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">
          "Vitamin and mineral deficiencies in inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Assessment of clinical risk for fracture
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of the clinical evaluation is to identify patients with IBD who are at high risk for bone loss and fracture. Many studies have demonstrated that low bone mineral density (BMD) is associated with an increased risk of fracture. However, there are several clinical risk factors for fracture that are independent of BMD, such as advancing age, prior history of fragility fracture, chronic corticosteroid use, low body mass index (BMI), parental history of hip fracture, cigarette smoking, and excess alcohol. Thus, fracture risk assessment should include evaluation of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical risk factors for osteoporosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         BMD measured by dual-energy x-ray absorptiometry (DXA)
        </p>
        <p>
        </p>
        <p>
         We typically perform a history and physical examination to elicit clinical risk factors for fracture and lifestyle factors that contribute to bone loss, including smoking, excessive alcohol, physical inactivity, and poor nutrition  (
         <a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         We obtain a BMD study (DXA spine and hip) in patients with IBD who are at higher risk for osteoporosis and fracture (previous fragility fracture, postmenopausal, male &gt;50 years, hypogonadism, or chronic [&gt;3 months] glucocorticoid therapy). If hyperparathyroidism is present or BMD at the spine or hip cannot be measured or interpreted, BMD may be measured at the forearm (33 percent radius) [
         <a href="#rid34">
          34
         </a>
         ]. This is largely in agreement with the American Gastroenterological Association (AGA) and British Society of Gastroenterologists guidelines [
         <a href="#rid1">
          1,35,36
         </a>
         ].
        </p>
        <p>
         Osteoporosis risk factor assessment is reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Dual-energy x-ray absorptiometry (DXA)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Skeletal site to measure'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Clinical risk factor assessment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Interpretation of DXA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The World Health Organization (WHO) has established a classification of BMD according to dual-energy x-ray absorptiometry (DXA) T-score that is the worldwide standard for diagnosis of osteoporosis in postmenopausal women and men &gt;50 years of age  (
         <a class="graphic graphic_table graphicRef53999" href="/z/d/graphic/53999.html" rel="external">
          table 2
         </a>
         ). However, in premenopausal women, men &lt;50 years of age, and children, the relationship between BMD and fracture risk is not well established. In these groups, Z-scores, not T-scores, should be used to interpret DXA scans. In addition, a diagnosis of osteoporosis in younger men, premenopausal women, and children should not be based upon DXA results alone. (See
         <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">
          "Overview of dual-energy x-ray absorptiometry", section on 'Diagnosis of osteoporosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2058.html" rel="external">
          "Epidemiology and etiology of premenopausal osteoporosis", section on 'Definitions'
         </a>
         .)
        </p>
        <p>
         The DXA criteria used to make therapeutic decisions are discussed below. (See
         <a class="local">
          'Patient selection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          BMD monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         While there are a number of approaches to monitoring bone mineral density (BMD), there is no consensus on the optimal approach. For patients with normal initial BMD results, the AGA recommends repeat testing in two to three years [
         <a href="#rid1">
          1
         </a>
         ]. Repeat testing may be warranted earlier (one to two years) in patients with more severe disease requiring prolonged corticosteroid therapy or less frequently (three to five years) in patients with mild disease.
        </p>
        <p>
         Patients with low bone mass on initial evaluation require further assessment.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Laboratory evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who have low bone mass, laboratory evaluation may help identify other causes of osteoporosis, such as renal or liver disease, vitamin D deficiency, and hyperparathyroidism  (
         <a class="graphic graphic_table graphicRef54926" href="/z/d/graphic/54926.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         Patients with a history of a low trauma fracture or low bone mass (T-score below -2.5 for postmenopausal women and men ≥50 years or Z-score below -2.0 for premenopausal women and men &lt;50 years) should have the following basic tests:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biochemistry profile (especially calcium, phosphorous, albumin, total protein, creatinine, liver enzymes including alkaline phosphatase, electrolytes)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         25-hydroxyvitamin D
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testosterone (men only)
        </p>
        <p>
        </p>
        <p>
         Measuring urinary calcium excretion (24-hour collection for calcium and creatinine) may identify patients with malabsorption (low urinary calcium level) and may be useful for monitoring response to calcium supplementation.
        </p>
        <p>
         Patients who have abnormalities on the initial laboratory testing or who have suspicious findings on history and physical examination may also require additional laboratory tests  (
         <a class="graphic graphic_table graphicRef62821" href="/z/d/graphic/62821.html" rel="external">
          table 4
         </a>
         ). The evaluation of osteoporosis is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women", section on 'Evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in men", section on 'Evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are limited data on the prevention and treatment of low bone mass in patients with IBD. The approach outlined below is developed from guidelines for the prevention and treatment of osteoporosis in postmenopausal women, men, and in patients taking glucocorticoids. Most important is to use the lowest dose of glucocorticoid that controls the IBD. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p>
         The treatment of low bone mass in patients with IBD includes lifestyle measures; correction of gonadal steroid and vitamin D deficiency, if these problems exist; minimizing glucocorticoid dose, duration, and type; and pharmacologic therapy, if necessary.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Lifestyle measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with IBD should adopt the same lifestyle measures that are recommended for all patients at risk for osteoporosis and fracture. These include regular weightbearing exercise, cessation of smoking, limiting alcohol intake, and preventing falls. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Lifestyle measures to reduce bone loss'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men", section on 'Lifestyle measures'
         </a>
         .)
        </p>
        <p>
         Physical activity and gravitational forces are important determinants of bone health, and physical activity can increase bone mineral density (BMD) in patients with osteopenia. In a 12-month trial of low-impact versus no exercise in 117 patients with Crohn disease (CD), nonsignificant gains in BMD occurred at the hip and spine in the group randomly assigned to the exercise program [
         <a href="#rid37">
          37
         </a>
         ]. Patients were asked to exercise at least twice a week and at least 10 times per month. Increases in BMD were significantly related to the number or exercise sessions completed.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Calcium and vitamin D
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vitamin D insufficiency and calcium malabsorption are common in patients with IBD. (See
         <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">
          "Vitamin and mineral deficiencies in inflammatory bowel disease", section on 'Vitamin D'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">
          "Vitamin and mineral deficiencies in inflammatory bowel disease", section on 'Calcium'
         </a>
         .)
        </p>
        <p>
         There are limited data on the skeletal effects of calcium and vitamin D supplementation in patients with IBD and low bone mass [
         <a href="#rid38">
          38,39
         </a>
         ]. As a general rule, patients with IBD and low bone mass should receive standard amounts of calcium (1200 mg/day, total diet plus supplement) and vitamin D (800 to 1000 international units/day [20 to 25 micrograms/day]). In some meta-analyses, supplementation with calcium and vitamin D has been shown to reduce fracture risk. (See
         <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">
          "Calcium and vitamin D supplementation in osteoporosis"
         </a>
         .)
        </p>
        <p>
         When considering vitamin D and calcium supplementation in patients with IBD, several important factors merit special attention:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vitamin D (800 to 1000 international units/day [20 to 25 micrograms/day]) and calcium (1200 mg/day) should be sufficient to minimize bone loss in patients with ulcerative colitis (UC) but not necessarily in patients with extensive CD of the small bowel, since the latter may have poor absorption of calcium and vitamin D. In such patients, the adequacy of the calcium and vitamin D supplementation should be assessed by measurements of serum and urinary calcium, serum albumin, 25-hydroxyvitamin D, and parathyroid hormone (PTH).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8829" href="/z/d/drug information/8829.html" rel="external">
          Calcium citrate
         </a>
         should generally be used instead of
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         because it may be absorbed better. (See
         <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">
          "Calcium and vitamin D supplementation in osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8829" href="/z/d/drug information/8829.html" rel="external">
          Calcium citrate
         </a>
         also does not appear to increase risk of urolithiasis [
         <a href="#rid40">
          40
         </a>
         ], which is elevated in these patients. (See
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Extraintestinal manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Treatment of hypogonadism
         </span>
         <span class="headingEndMark">
          —
         </span>
         High doses of glucocorticoids inhibit the secretion of gonadotropins and thereby reduce the production of gonadal steroids. A woman of premenopausal age with IBD who has amenorrhea or severe oligomenorrhea should therefore be evaluated for hypogonadism by measurement of serum
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         and gonadotropins. If hypogonadism is confirmed, it should be treated. (See
         <a class="medical medical_review" href="/z/d/html/7402.html" rel="external">
          "Evaluation and management of secondary amenorrhea", section on 'Initial evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6640.html" rel="external">
          "Treatment of hypopituitarism", section on 'Females'
         </a>
         .)
        </p>
        <p>
         In postmenopausal women, menopausal hormone therapy is not considered a first-line option for fracture prevention [
         <a href="#rid41">
          41,42
         </a>
         ]. The approach to pharmacotherapy for bone disease in postmenopausal women is reviewed below. Treatment options and the relative benefits and risks of menopausal hormone therapy are reviewed elsewhere. (See
         <a class="local">
          'Pharmacologic therapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7428.html" rel="external">
          "Menopausal hormone therapy in the prevention and treatment of osteoporosis"
         </a>
         .)
        </p>
        <p>
         High-dose glucocorticoid therapy can also lower serum testosterone concentrations in men [
         <a href="#rid30">
          30
         </a>
         ], so men with IBD who take glucocorticoids should have periodic measurements of serum testosterone, and testosterone therapy should be offered if the concentration is low. (See
         <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">
          "Clinical features and diagnosis of male hypogonadism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">
          "Testosterone treatment of male hypogonadism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Pharmacologic therapy
         </span>
        </p>
        <p class="headingAnchor" id="H260141132">
         <span class="h3">
          Patient selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few data that inform the decision as to which patients with IBD should receive pharmacologic therapy for bone disease [
         <a href="#rid2">
          2
         </a>
         ]. In the absence of data specifically in patients with IBD, recommendations for therapy are based upon data in men and postmenopausal women with osteoporosis and in patients receiving high-dose glucocorticoids. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p>
         Patients with the highest risk for fracture, based on BMD and clinical risk factors, are the ones most likely to benefit from drug therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Men &gt;50 years and postmenopausal women with IBD and established osteoporosis (history of fragility fracture or BMD T-score ≤-2.5) are candidates for pharmacologic therapy as are similar adults without IBD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Men &gt;50 years and postmenopausal women without established osteoporosis should be assessed using the Fracture Risk Assessment Tool (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2028" target="_blank">
          FRAX
         </a>
         ). In the United States, a reasonable cutpoint to indicate high risk is a 10-year probability of hip or combined major osteoporotic fracture of ≥3 and 20 percent, respectively. Fracture risk assessment, including the FRAX tool and its limitations, is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Fracture risk assessment tool'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Men &gt;50 years and postmenopausal women who have a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2028" target="_blank">
          FRAX
         </a>
         -calculated absolute risk below these cutpoints, who are receiving ≥7.5 mg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or its equivalent for an anticipated duration of ≥3 months, are also candidates for therapy.
        </p>
        <p>
        </p>
        <p>
         The FRAX tool was not developed for use in premenopausal women or men &lt;40 years. Fracture risk in these patients with IBD is not clearly defined, so treatment must be extrapolated from data in premenopausal women and men taking high-dose glucocorticoids. These recommendations are reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Premenopausal women and younger men'
         </a>
         .)
        </p>
        <p>
         One area of uncertainty is the selection of hypogonadal men, who are already treated with testosterone therapy, for additional pharmacologic therapy. There are no clinical trial data that address this question and, in particular, the effect of testosterone on fracture risk has not been evaluated. For hypogonadal men who are at high risk for fracture (eg, chronic high-dose glucocorticoid therapy), we suggest the addition of pharmacologic therapy to testosterone therapy. The rationale for this recommendation is reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men", section on 'Patient selection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Candidates for pharmacologic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H260141362">
         <span class="h3">
          Choice of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For men and postmenopausal women with IBD who are candidates for therapy, we suggest oral bisphosphonates as the first-line pharmacologic option. In small, randomized trials in men and pre- and postmenopausal women with IBD, bisphosphonates have been shown to prevent bone loss [
         <a href="#rid43">
          43-45
         </a>
         ]. These trials were not designed to assess fracture as a primary outcome.
        </p>
        <p>
         Although there are no trials comparing the relative efficacy of the individual bisphosphonates, we prefer
         <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">
          alendronate
         </a>
         or
         <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">
          risedronate
         </a>
         given orally once a week. Intravenous (IV)
         <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">
          zoledronic acid
         </a>
         is a good option for those who cannot tolerate or absorb bisphosphonates orally.
        </p>
        <p>
         For premenopausal women with fractures or accelerated bone loss and normal menstrual function (ie, no indication for treatment of hypogonadism), we generally suggest bisphosphonates. However, it is important to consider the potential for harm to the fetus in women who become pregnant who are currently receiving or were recently treated with bisphosphonates. (See
         <a class="local">
          'Treatment of hypogonadism'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis", section on 'Antiresorptive therapy with bisphosphonates'
         </a>
         .)
        </p>
        <p>
         Other available osteoporosis drugs can be considered for patients with IBD and osteoporosis who are intolerant of any bisphosphonate or who fail bisphosphonate therapy (fracture with loss of BMD in spite of compliance with therapy), or who have especially severe osteoporosis, although there are no data about use of these drugs specifically in IBD. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H260141369">
         <span class="h3">
          Efficacy
         </span>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h4">
          Bisphosphonates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bisphosphonates attenuate corticosteroid-induced bone loss, so they are frequently used for the prevention and treatment of osteoporosis in patients taking corticosteroids. (See
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Bisphosphonates'
         </a>
         .)
        </p>
        <p>
         Because corticosteroid treatment is a risk factor for IBD-associated bone loss, bisphosphonates are also frequently used for the prevention of bone loss in patients with IBD. In several small, clinical trials in men and pre- and postmenopausal women with IBD, oral bisphosphonates were shown to improve BMD compared with placebo [
         <a href="#rid43">
          43-45
         </a>
         ]. As an example, in a 12-month trial of
         <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">
          risedronate
         </a>
         (35 mg weekly) versus placebo in 90 postmenopausal women with IBD in remission, BMD (lumbar spine, trochanter, and femoral neck) significantly increased in the risedronate group compared with placebo [
         <a href="#rid45">
          45
         </a>
         ]. The incidence of vertebral fractures, a secondary endpoint, was significantly lower in the risedronate group (12.5 versus 34 percent).
        </p>
        <p>
         IV bisphosphonates are an alternative option for patients unable to tolerate or absorb oral bisphosphonates. In a small trial, IV
         <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">
          ibandronate
         </a>
         (1 mg every three months) significantly improved BMD in patients with CD [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">
          "Bisphosphonate therapy for the treatment of osteoporosis", section on 'Choice of bisphosphonate'
         </a>
         .)
        </p>
        <p>
         IV
         <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">
          zoledronic acid
         </a>
         reduces bone loss and fracture in postmenopausal women with osteoporosis, reduces recurrent fracture in adults with hip fracture, and reduces bone loss in corticosteroid-induced osteoporosis. It is likely effective in patients with IBD, but such data are not yet available. (See
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Bisphosphonates'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">
          "Bisphosphonate therapy for the treatment of osteoporosis", section on 'Choice of bisphosphonate'
         </a>
         .)
        </p>
        <p>
         Bisphosphonates should be used with caution in premenopausal women because of insufficient information on the potential for harm to the fetus in women who become pregnant while currently or recently receiving bisphosphonates. In these patients who require drug treatment, long-lasting drugs like
         <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">
          zoledronic acid
         </a>
         and
         <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">
          alendronate
         </a>
         should be avoided in favor of drugs that accumulate less (such as
         <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">
          risedronate
         </a>
         or
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         ) or not at all (such as PTH) [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis", section on 'Antiresorptive therapy with bisphosphonates'
         </a>
         .)
        </p>
        <p>
         The dosing, side effects, and contraindications of bisphosphonates are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">
          "Bisphosphonate therapy for the treatment of osteoporosis", section on 'Practical management issues'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h4">
          Anabolic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The indications for treatment with an anabolic agent (eg,
         <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">
          teriparatide
         </a>
         ) in patients with IBD are the same as the indications for anabolic treatment in general. Anabolic therapy is reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Selection of anabolic agent'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men", section on 'Severe osteoporosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Parathyroid hormone'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis", section on 'Anabolic therapy with teriparatide'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">
          "Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Patients with inflammatory bowel disease (IBD) are at risk for osteoporosis and fracture for several reasons, including disease-related inflammatory activity, glucocorticoid therapy, hypogonadism, and nutritional deficiencies. Advanced age and low body mass index (BMI) further increase risk. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fracture risk assessment
         </strong>
         – The goal of the clinical evaluation is to identify patients with IBD who are at high risk for bone loss and fracture. We perform a history and physical examination to elicit clinical risk factors for fracture  (
         <a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">
          table 1
         </a>
         ). We obtain a bone mineral density (BMD) study (dual-energy x-ray absorptiometry [DXA] spine and hip) in patients with IBD who are at higher risk for osteoporosis and fracture (previous fragility fracture, postmenopausal, male &gt;50 years, hypogonadism, or chronic [&gt;3 months] glucocorticoid therapy). (See
         <a class="local">
          'Assessment of clinical risk for fracture'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory evaluation
         </strong>
         – Patients with a history of a fragility fracture or low bone mass by initial DXA require laboratory evaluation to identify possible secondary causes of osteoporosis  (
         <a class="graphic graphic_table graphicRef54926" href="/z/d/graphic/54926.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef62821" href="/z/d/graphic/62821.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Laboratory evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lifestyle measures
         </strong>
         – We counsel patients with IBD and low bone mass about lifestyle behaviors that will improve their bone health, including exercise, stopping smoking, means of preventing falls, and avoiding heavy alcohol use. (See
         <a class="local">
          'Lifestyle measures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcium and vitamin D
         </strong>
         – We suggest calcium and vitamin D supplementation in patients with IBD, low bone mass, and inadequate dietary intake (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Although the optimal total intake (diet plus supplement) has not been clearly established in this patient population, approximately 1200 mg of calcium and 800 to 1000 international units (20 to 25 micrograms) of vitamin D daily are the typical doses used in patients with low bone mass. (See
         <a class="local">
          'Calcium and vitamin D'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with malabsorption may require higher doses of calcium and vitamin D. Adequacy of the dose can be assessed by measuring serum and urinary calcium, albumin, parathyroid hormone (PTH), and 25-hydroxyvitamin D. (See
         <a class="local">
          'Calcium and vitamin D'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">
          "Calcium and vitamin D supplementation in osteoporosis", section on 'Underlying gastrointestinal disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally use
         <a class="drug drug_general" data-topicid="8829" href="/z/d/drug information/8829.html" rel="external">
          calcium citrate
         </a>
         , which is better absorbed than
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         , in patients with IBD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of hypogonadism
         </strong>
         – Treatment of hypogonadism is generally initiated in premenopausal women with IBD and menstrual irregularities while taking glucocorticoids. Testosterone replacement therapy (if not contraindicated) is generally initiated in men with IBD and symptomatic hypogonadism. (See
         <a class="local">
          'Treatment of hypogonadism'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6640.html" rel="external">
          "Treatment of hypopituitarism", section on 'Females'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">
          "Clinical features and diagnosis of male hypogonadism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">
          "Testosterone treatment of male hypogonadism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacotherapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patient selection
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Postmenopausal women and men aged &gt;50 years
         </strong>
         – For postmenopausal women and for men &gt;50 years of age with IBD and T-scores below -2.5 or history of a fragility fracture, we recommend pharmacologic therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For high-risk postmenopausal women and men &gt;50 years of age with IBD and T-scores between -1.0 and -2.5, we also suggest pharmacologic therapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Our definition of high risk, which also may be cost effective in some settings, is a Fracture Risk Assessment Tool (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2028" target="_blank">
          FRAX
         </a>
         ) 10-year probability of hip or combined major osteoporotic fracture of ≥3 or 20 percent, respectively. (See
         <a class="local">
          'Patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For postmenopausal women and men &gt;50 years with IBD who have lower risk by
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2028" target="_blank">
          FRAX
         </a>
         , we suggest pharmacologic therapy if they are taking ≥7.5 mg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or its equivalent for an anticipated duration of ≥3 months (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Premenopausal women and men aged &lt;50 years
         </strong>
         – There are few data that inform the decision as to which premenopausal women and men &lt;50 years with IBD should receive pharmacologic therapy for bone disease. Recommendations for this population are extrapolated from limited data in premenopausal women and younger men taking glucocorticoids. These recommendations are reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Premenopausal women and younger men'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Choice of therapy
         </strong>
         – For pharmacologic therapy, we suggest bisphosphonates as first-line therapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Other available agents that have been shown to be effective for the treatment of osteoporosis are options, but they have not been studied in patients with IBD. (See
         <a class="local">
          'Choice of therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Medical therapy in premenopausal women with IBD should take into account the insufficient information on the potential for harm to the fetus in women who become pregnant while taking bisphosphonates shortly after discontinuing them. (See
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis", section on 'Antiresorptive therapy with bisphosphonates'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We prefer weekly oral
         <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">
          alendronate
         </a>
         or
         <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">
          risedronate
         </a>
         . Intravenous (IV) bisphosphonate formulations are available for patients who cannot tolerate or absorb oral bisphosphonates or who have difficulty with dosing requirements. (See
         <a class="local">
          'Choice of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4033284180">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 2006; :59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Compston J. Osteoporosis in inflammatory bowel disease. Gut 2003; 52:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med 2009; 122:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szafors P, Che H, Barnetche T, et al. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int 2018; 29:2389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998; 114:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Targownik LE, Bernstein CN, Nugent Z, Leslie WD. Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol 2013; 11:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992; 37:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol 2004; 39:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SH, Kim HJ, Yang SK, et al. Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea. J Gastroenterol Hepatol 2000; 15:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vestergaard P, Krogh K, Rejnmark L, et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Targownik LE, Bernstein CN, Nugent Z, et al. Inflammatory bowel disease and the risk of fracture after controlling for FRAX. J Bone Miner Res 2013; 28:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loftus EV Jr, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002; 123:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vestergaard P, Mosekilde L. Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002; 156:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockbrügger RW, Schoon EJ, Bollani S, et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 2002; 16:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal M, Arora S, Li J, et al. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep 2011; 9:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen B, Remzi FH, Oikonomou IK, et al. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol 2009; 104:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Targownik LE, Leslie WD, Carr R, et al. Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease. Calcif Tissue Int 2012; 91:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulte CM, Dignass AU, Goebell H, et al. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000; 119:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm Bowel Dis 2005; 11:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silvennoinen JA, Karttunen TJ, Niemelä SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quint AR, Kaiser FE. Gonadotropin determinations and thyrotropin-releasing hormone and luteinizing hormone-releasing hormone testing in critically ill postmenopausal women with hypothyroxinemia. J Clin Endocrinol Metab 1985; 60:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odell WD. Testosterone treatment of men treated with glucocorticoids. Arch Intern Med 1996; 156:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Driscoll RH Jr, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982; 83:1252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection. Am J Clin Nutr 1991; 54:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Napartivaumnuay N, Gramlich L. The Prevalence of Vitamin D Insufficiency and Deficiency and Their Relationship with Bone Mineral Density and Fracture Risk in Adults Receiving Long-Term Home Parenteral Nutrition. Nutrients 2017; 9.
          </a>
         </li>
         <li class="breakAll">
          2019 ISCD Official Positions - Adult. Available at: https://iscd.org/learn/official-positions/adult-positions/ (Accessed on July 26, 2023).
         </li>
         <li class="breakAll">
          Lewis NR, Scott BB. Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease. London (UK): British Society of Gastroenterology, 2007 www.guideline.gov/summary/summary.aspx?doc_id=14259 (Accessed on September 07, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atreja A, Aggarwal A, Licata AA, Lashner BA. Low body mass index can identify majority of osteoporotic inflammatory bowel disease patients missed by current guidelines. ScientificWorldJournal 2012; 2012:807438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson RJ, Krzywicki T, Almond L, et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology 1998; 115:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelsang H, Ferenci P, Resch H, et al. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakhaee K, Poindexter JR, Griffith CS, Pak CY. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. J Urol 2004; 172:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006; 101:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomba S, Orio F Jr, Manguso F, et al. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. Osteoporos Int 2005; 16:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Tirpitz C, Klaus J, Steinkamp M, et al. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003; 17:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen KE, Wilson HA, Zapalowski C, et al. Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 2011; 26:1989.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2028 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12612917" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : AGA technical review on osteoporosis in gastrointestinal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16782623" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Skeletal morbidity in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12477761" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Osteoporosis in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19559158" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Osteoporosis in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29909470" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9135518" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7926456" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9558278" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Bone mineral density assessment in children with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23103821" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1505291" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Low bone mineral density in patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7835582" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Metabolic bone assessment in patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9071937" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Reduced bone density in patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7754804" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15000276" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10847438" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11085842" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10644310" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Fracture risk is increased in Crohn's disease, but not in ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23239264" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Inflammatory bowel disease and the risk of fracture after controlling for FRAX.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12145800" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12076883" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12182752" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21935582" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Bone, inflammation, and inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19262520" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22983212" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11040178" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Genetic factors determine extent of bone loss in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15803021" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15753532" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7672685" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A controlled study of bone mineral density in patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3919044" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Gonadotropin determinations and thyrotropin-releasing hormone and luteinizing hormone-releasing hormone testing in critically ill postmenopausal women with hypothyroxinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639006" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Testosterone treatment of men treated with glucocorticoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6982188" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Vitamin D deficiency and bone disease in patients with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1652198" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28489034" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The Prevalence of Vitamin D Insufficiency and Deficiency and Their Relationship with Bone Mineral Density and Fracture Risk in Adults Receiving Long-Term Home Parenteral Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28489034" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The Prevalence of Vitamin D Insufficiency and Deficiency and Their Relationship with Bone Mineral Density and Fracture Risk in Adults Receiving Long-Term Home Parenteral Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28489034" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The Prevalence of Vitamin D Insufficiency and Deficiency and Their Relationship with Bone Mineral Density and Fracture Risk in Adults Receiving Long-Term Home Parenteral Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22645457" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Low body mass index can identify majority of osteoporotic inflammatory bowel disease patients missed by current guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9649456" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8899087" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8590154" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15311008" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Stone forming risk of calcium citrate supplementation in healthy postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12117397" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14519707" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10982756" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16405543" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15928801" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12641503" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21721042" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
